Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
HCW Biologics Inc. (HCWB)
USD4.30
-0.20 (-4.44%)
US NASDAQ Healthcare Biotechnology
Address
2929 North Commerce Parkway 33025
Miramar, FL, US
Miramar, FL, US
CEO
Hing C. Wong
Website
hcwbiologics.com
IPO
2021-07-20
CIK 1828673 ISIN US40423R2040
Description
HCW Biologics Inc. operates as a preclinical-stage biopharmaceutical firm, primarily engaged in the discovery and advancement of novel immunotherapies. Its research and development efforts are focused on addressing chronic, low-grade inflammation and a spectrum of age-related diseases. The company's leading therapeutic candidates include HCW9218, an injectable immunotherapeutic designed for patients with a variety of cancers, such as pancreatic, ovarian, breast, prostate, and colorectal, as well as for pulmonary fibrosis. Another key product, HCW9302, targets autoimmune conditions like alopecia areata and various metabolic disorders. Beyond these, HCW Biologics is also developing HCW9201, a cell-based therapy currently in Phase II clinical trials for the treatment of relapsed/refractory acute myeloid leukemia. Additionally, HCW9206 is under development specifically for acute myeloid leukemia. Incorporated in 2018, the company's corporate headquarters are situated in Miramar, Florida.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD4.30
-0.20 (-4.44%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
2M
Beta
2.30
Float Shares
1.79M
Free Float %
85.8%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -3.55% | +5.15% | -2.60% | -48.16% | -88.77% | -65.28% | -96.17% | -99.43% | -99.87% | -99.87% | -99.87% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (3 ratings, all time)
Buy
Price Targets & DCF
Current price
4.30
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-6.14
Distress
Piotroski F-Score
5 / 9
Average
MOAT Score
0 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
5 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-97.9% Q1'26: +129,080.7% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-1,280.5% Q1'26: +840.0% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-17,885.4% Q1'26: -24.1% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-12,371.7% Q1'26: +0.0% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-88.0% Q1'26: +0.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%-94.6% ★ Q1'26: -87.9% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-1.20× Q1'26: 0.51× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
6.72M
est: 5.39M (+24.6%)
|
2.84M
est: 3.92M (-27.6%)
|
2.57M
est: 9.17M (-72.0%)
|
54.2K
est: 27.0K (+100.9%)
|
900.0K
900.0K – 900.0K
+3,233.3% YoY
|
33.73M
33.73M – 33.73M
+3,647.8% YoY
|
45.65M
45.65M – 45.65M
+35.3% YoY
|
6.4K
6.4K – 6.4K
-100.0% YoY
|
3.8K
3.8K – 3.8K
-41.3% YoY
|
| EBITDA |
-14.06M
est: -3.24M (-334.3%)
|
-23.58M
est: -2.35M (-901.7%)
|
-27.68M
est: -5.50M (-403.0%)
|
-5.67M
est: -16.2K (-34,885.6%)
|
-540.0K
-540.0K – -540.0K
-3,233.3% YoY
|
-20.24M
-20.24M – -20.24M
-3,647.8% YoY
|
-27.39M
-27.39M – -27.39M
-35.3% YoY
|
-3.9K
-3.9K – -3.9K
+100.0% YoY
|
-2.3K
-2.3K – -2.3K
+41.3% YoY
|
| EBIT |
-14.77M
est: -3.24M (-356.5%)
|
-24.71M
est: -2.35M (-949.9%)
|
-28.87M
est: -5.50M (-424.5%)
|
-6.71M
est: -16.2K (-41,316.3%)
|
-540.0K
-540.0K – -540.0K
-3,233.3% YoY
|
-20.24M
-20.24M – -20.24M
-3,647.8% YoY
|
-27.39M
-27.39M – -27.39M
-35.3% YoY
|
-3.9K
-3.9K – -3.9K
+100.0% YoY
|
-2.3K
-2.3K – -2.3K
+41.3% YoY
|
| Net Income |
-14.90M
est: -656.89M (+97.7%)
|
-24.99M
est: -2.19M (-1,041.1%)
|
-30.02M
est: -47.83M (+37.2%)
|
-7.96M
est: -10.97M (+27.4%)
|
-2.01M
-2.01M – -2.01M
+81.6% YoY
|
-1.15M
-1.15M – -1.15M
+42.7% YoY
|
-964.9K
-964.9K – -964.9K
+16.4% YoY
|
-839.1K
-839.1K – -839.1K
+13.0% YoY
|
-944.0K
-944.0K – -944.0K
-12.5% YoY
|
| SGA |
7.99M
est: 17.19M (-53.5%)
|
13.08M
est: 123.45M (-89.4%)
|
21.95M
est: 288.64M (-92.4%)
|
7.70M
est: 849.7K (+806.4%)
|
28.32M
28.32M – 28.32M
+3,233.3% YoY
|
1.06B
1.06B – 1.06B
+3,647.8% YoY
|
1.44B
1.44B – 1.44B
+35.3% YoY
|
202.3K
202.3K – 202.3K
-100.0% YoY
|
118.7K
118.7K – 118.7K
-41.3% YoY
|
| EPS |
-0.41
est: -16.93 (+97.6%)
|
-0.70
est: -1.04 (+33.0%)
|
-0.77
est: -22.80 (+96.6%)
|
-10.63
est: -5.23 (-103.3%)
|
-0.96
-0.96 – -0.96
+81.6% YoY
|
-0.55
-0.55 – -0.55
+42.7% YoY
|
-0.46
-0.46 – -0.46
+16.4% YoY
|
-0.40
-0.40 – -0.40
+13.0% YoY
|
-0.45
-0.45 – -0.45
-12.5% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-14 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-13 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-01 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-25.70M
OE per share TTM
-8.51
Owner's Yield
-1,405.68%
Maintenance CapEx ratio
250.57%
Maint CapEx / Avg PPE
490.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
1
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Hing C. Wong, Ph.D. | 15.26M | 42.70% | 11.13M | 4.13M | 11.13M | 4.13M | IN | — | 2021-08-02 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 1 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard Extended Market ETF VXF | 0.00% | 23.3K | 0.05% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
12
Sells
0
Shares acquired
165.9K
Shares disposed
—
Cash buys
12.00
Cash sales
—
Net activity
+165,868
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-05-16 | Wong Hing C | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 8,054 | 7.45 | 60.0K | 501,911 | D | ↗ |
| 2025-05-16 | Winer Gary M | Director | P-Purchase | A | Common Stock | 1,342 | 7.45 | 10.0K | 4,075 | D | ↗ |
| 2025-05-16 | GARRETT SCOTT T | Director | P-Purchase | A | Common Stock | 13,423 | 7.45 | 100.0K | 25,505 | D | ↗ |
| 2025-05-08 | Wong Hing C | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 92,500 | 26.00 | 2.41M | 493,857 | D | ↗ |
| 2025-05-08 | Winer Gary M | Director | P-Purchase | A | Common Stock | 2,308 | 26.00 | 60.0K | 2,733 | D | ↗ |
| 2025-05-08 | Greene Rick S. | Director | P-Purchase | A | Common Stock | 962 | 26.00 | 25.0K | 2,066 | D | ↗ |
| 2025-05-08 | GARRETT SCOTT T | Director | P-Purchase | A | Common Stock | 5,385 | 26.00 | 140.0K | 12,082 | D | ↗ |
| 2025-05-08 | Flowers Lee | Officer | P-Purchase | A | Common Stock | 962 | 26.00 | 25.0K | 5,720 | D | ↗ |
| 2025-05-08 | Byam Rebecca | Officer | P-Purchase | A | Common Stock | 8,462 | 26.00 | 220.0K | 43,010 | D | ↗ |
| 2025-05-07 | Wong Hing C | Director / Officer / 10% Owner | P-Purchase | A | Common Stock Purchase Warrant | 46,250 | 26.00 | 1.20M | 46,250 | D | ↗ |
| 2025-05-07 | Winer Gary M | Director | P-Purchase | A | Common Stock Purchase Warrant | 1,154 | 26.00 | 30.0K | 1,154 | D | ↗ |
| 2025-05-07 | Greene Rick S. | Director | P-Purchase | A | Common Stock Purchase Warrant | 481 | 26.00 | 12.5K | 481 | D | ↗ |
| 2025-05-07 | GARRETT SCOTT T | Director | P-Purchase | A | Common Stock Purchase Warrant | 2,692 | 26.00 | 70.0K | 2,692 | D | ↗ |
| 2025-05-07 | Flowers Lee | Officer | P-Purchase | A | Common Stock Purchase Warrant | 481 | 26.00 | 12.5K | 481 | D | ↗ |
| 2025-05-07 | Byam Rebecca | Officer | P-Purchase | A | Common Stock Purchase Warrant | 4,231 | 26.00 | 110.0K | 4,231 | D | ↗ |
| 2024-06-14 | Winer Gary M | Director | A-Award | A | Stock Option (Right to Buy) | 12,500 | 1.12 | 14.0K | 12,500 | — | ↗ |
| 2024-06-14 | Greene Rick S. | Director | A-Award | A | Stock Option (Right to Buy) | 12,500 | 1.12 | 14.0K | 12,500 | — | ↗ |
| 2024-06-14 | Giles Lisa M. | Director | A-Award | A | Stock Option (Right to Buy) | 12,500 | 1.12 | 14.0K | 12,500 | — | ↗ |
| 2024-06-14 | GARRETT SCOTT T | Director | A-Award | A | Stock Option (Right to Buy) | 12,500 | 1.12 | 14.0K | 12,500 | — | ↗ |
| 2024-02-20 | Wong Hing C | Director / Officer | A-Award | A | Common Stock | 739,288 | 1.40 | 1.04M | 16,054,156 | — | ↗ |
| 2024-02-20 | Greene Rick S. | Director | A-Award | A | Common Stock | 35,714 | 1.40 | 50.0K | 44,125 | — | ↗ |
| 2024-02-20 | Giles Lisa M. | Director | A-Award | A | Common Stock | 35,715 | 1.40 | 50.0K | 35,815 | — | ↗ |
| 2024-02-20 | GARRETT SCOTT T | Director | A-Award | A | Common Stock | 142,858 | 1.40 | 200.0K | 267,858 | — | ↗ |
| 2024-02-20 | Flowers Lee | Officer | A-Award | A | Common Stock | 71,429 | 1.40 | 100.0K | 190,238 | — | ↗ |
| 2024-02-20 | Byam Rebecca | Officer | A-Award | A | Common Stock | 760,714 | 1.40 | 1.06M | 1,381,909 | — | ↗ |
| 2023-12-11 | Rhode Peter | Officer | M-Exempt | A | Common Stock | 14,000 | 0.14 | 2.0K | 77,500 | — | ↗ |
| 2023-12-08 | Flowers Lee | Officer | M-Exempt | A | Common Stock | 7,501 | 0.14 | 1.1K | 118,809 | — | ↗ |
| 2023-11-17 | Rhode Peter | Officer | M-Exempt | A | Common Stock | 15,000 | 0.14 | 2.1K | 63,500 | — | ↗ |
| 2023-10-19 | Byam Rebecca | Officer | M-Exempt | A | Common Stock | 47,249 | 0.14 | 6.6K | 621,195 | — | ↗ |
| 2023-09-14 | Wong Hing C | Director / Officer | P-Purchase | A | Common Stock | 1,800 | 2.08 | 3.7K | 15,314,868 | — | ↗ |
| 2023-09-14 | Winer Gary M | Director | P-Purchase | A | Common Stock | 879 | 2.05 | 1.8K | 17,000 | — | ↗ |
| 2023-09-13 | Winer Gary M | Director | P-Purchase | A | Common Stock | 46 | 2.00 | 92.00 | 15,959 | — | ↗ |
| 2023-09-13 | Byam Rebecca | Officer | P-Purchase | A | Common Stock | 5,000 | 2.10 | 10.5K | 573,946 | — | ↗ |
| 2023-09-12 | Winer Gary M | Director | P-Purchase | A | Common Stock | 500 | 2.05 | 1.0K | 15,413 | — | ↗ |
| 2023-09-12 | Byam Rebecca | Officer | P-Purchase | A | Common Stock | 5,000 | 2.09 | 10.4K | 568,946 | — | ↗ |
| 2023-09-11 | Winer Gary M | Director | P-Purchase | A | Common Stock | 99 | 2.05 | 202.95 | 14,913 | — | ↗ |
| 2023-09-11 | Byam Rebecca | Officer | P-Purchase | A | Common Stock | 5,000 | 2.05 | 10.3K | 563,946 | — | ↗ |
| 2023-09-08 | Winer Gary M | Director | P-Purchase | A | Common Stock | 1 | 1.90 | 1.90 | 14,814 | — | ↗ |
| 2023-09-08 | Byam Rebecca | Officer | P-Purchase | A | Common Stock | 5,000 | 2.02 | 10.1K | 558,946 | — | ↗ |
| 2023-09-07 | Winer Gary M | Director | P-Purchase | A | Common Stock | 63 | 1.95 | 122.85 | 14,813 | — | ↗ |
| 2023-09-07 | Byam Rebecca | Officer | P-Purchase | A | Common Stock | 5,000 | 1.95 | 9.7K | 553,946 | — | ↗ |
| 2023-09-06 | Byam Rebecca | Officer | P-Purchase | A | Common Stock | 5,000 | 1.95 | 9.7K | 548,946 | — | ↗ |
| 2023-09-05 | Winer Gary M | Director | P-Purchase | A | Common Stock | 400 | 1.75 | 700.00 | 14,750 | — | ↗ |
| 2023-06-13 | Winer Gary M | Director | A-Award | A | Stock Option (Right to Buy) | 12,500 | 2.01 | 25.1K | 12,500 | — | ↗ |
| 2023-06-13 | Greene Rick S. | Director | A-Award | A | Stock Option (Right to Buy) | 12,500 | 2.01 | 25.1K | 12,500 | — | ↗ |
| 2023-06-13 | Giles Lisa M. | Director | A-Award | A | Stock Option (Right to Buy) | 12,500 | 2.01 | 25.1K | 12,500 | — | ↗ |
| 2023-06-13 | GARRETT SCOTT T | Director | A-Award | A | Stock Option (Right to Buy) | 12,500 | 2.01 | 25.1K | 12,500 | — | ↗ |
| 2023-06-09 | Byam Rebecca | Officer | P-Purchase | A | Common Stock | 20,000 | 2.06 | 41.3K | 543,946 | — | ↗ |
| 2023-06-08 | Flowers Lee | Officer | P-Purchase | A | Common Stock | 10,000 | 2.16 | 21.6K | 111,308 | — | ↗ |
| 2023-06-08 | Byam Rebecca | Officer | P-Purchase | A | Common Stock | 4,696 | 2.21 | 10.4K | 523,946 | — | ↗ |
| 2023-06-07 | Byam Rebecca | Officer | P-Purchase | A | Common Stock | 20,000 | 2.03 | 40.6K | 519,250 | — | ↗ |
| 2023-06-06 | Byam Rebecca | Officer | P-Purchase | A | Common Stock | 19,062 | 1.82 | 34.8K | 499,250 | — | ↗ |
| 2023-06-05 | Byam Rebecca | Officer | P-Purchase | A | Common Stock | 20,000 | 1.67 | 33.3K | 480,188 | — | ↗ |
| 2023-06-02 | Wong Hing C | Director / Officer | P-Purchase | A | Common Stock | 800 | 1.54 | 1.2K | 15,313,068 | — | ↗ |
| 2023-06-01 | Wong Hing C | Director / Officer | P-Purchase | A | Common Stock | 800 | 1.62 | 1.3K | 15,312,268 | — | ↗ |
| 2023-05-31 | Wong Hing C | Director / Officer | P-Purchase | A | Common Stock | 2,000 | 1.55 | 3.1K | 15,311,468 | — | ↗ |
| 2023-05-31 | Winer Gary M | Director | P-Purchase | A | Common Stock | 500 | 1.50 | 750.00 | 14,350 | — | ↗ |
| 2023-05-30 | Wong Hing C | Director / Officer | P-Purchase | A | Common Stock | 3,000 | 1.55 | 4.7K | 15,309,468 | — | ↗ |
| 2023-05-30 | Winer Gary M | Director | P-Purchase | A | Common Stock | 850 | 1.52 | 1.3K | 13,850 | — | ↗ |
| 2023-05-26 | Byam Rebecca | Officer | P-Purchase | A | Common Stock | 20,000 | 1.66 | 33.2K | 460,188 | — | ↗ |
| 2023-05-25 | Byam Rebecca | Officer | P-Purchase | A | Common Stock | 20,000 | 1.62 | 32.3K | 440,188 | — | ↗ |
| 2023-05-24 | Byam Rebecca | Officer | P-Purchase | A | Common Stock | 20,000 | 1.61 | 32.2K | 420,188 | — | ↗ |
| 2023-05-23 | Byam Rebecca | Officer | P-Purchase | A | Common Stock | 5,036 | 1.57 | 7.9K | 400,188 | — | ↗ |
| 2023-05-22 | Byam Rebecca | Officer | P-Purchase | A | Common Stock | 33,450 | 1.53 | 51.0K | 395,152 | — | ↗ |
| 2022-11-02 | Byam Rebecca | Officer | M-Exempt | A | Common Stock | 33,750 | 0.14 | 4.7K | 361,702 | — | ↗ |
| 2022-09-08 | Wong Hing C | Officer | P-Purchase | A | Common Stock | 6,000 | 2.70 | 16.2K | 15,306,468 | — | ↗ |
| 2022-09-02 | Wong Hing C | Officer | P-Purchase | A | Common Stock | 6,000 | 2.58 | 15.5K | 15,296,468 | — | ↗ |
| 2022-08-30 | Byam Rebecca | Officer | P-Purchase | A | Common Stock | 10,000 | 2.56 | 25.6K | 282,952 | — | ↗ |
| 2022-08-26 | Byam Rebecca | Officer | P-Purchase | A | Common Stock | 10,000 | 2.54 | 25.4K | 255,752 | — | ↗ |
| 2022-08-24 | Byam Rebecca | Officer | P-Purchase | A | Common Stock | 50,000 | 2.50 | 125.2K | 205,452 | — | ↗ |
| 2022-06-15 | Winer Gary M | Director | A-Award | A | Stock Option (Right to Buy) | 41,841 | 0.00 | — | 41,841 | — | ↗ |
| 2022-06-15 | Greene Rick S. | Director | A-Award | A | Stock Option (Right to Buy) | 41,841 | 0.00 | — | 41,841 | — | ↗ |
| 2022-06-15 | Giles Lisa M. | Director | A-Award | A | Stock Option (Right to Buy) | 41,841 | 2.39 | 100.0K | 41,841 | — | ↗ |
| 2022-06-15 | GARRETT SCOTT T | Director | A-Award | A | Stock Option (Right to Buy) | 41,841 | 0.00 | — | 41,841 | — | ↗ |
| 2022-06-13 | Byam Rebecca | Officer | P-Purchase | A | Common Stock | 58,856 | 2.46 | 145.0K | 155,452 | — | ↗ |
| 2022-06-10 | Wong Hing C | Officer | P-Purchase | A | Common Stock | 1,520 | 2.19 | 3.3K | 15,286,468 | — | ↗ |
| 2022-06-09 | Winer Gary M | Director | P-Purchase | A | Common Stock | 1,000 | 2.20 | 2.2K | 11,500 | — | ↗ |
| 2022-06-08 | Winer Gary M | Director | P-Purchase | A | Common Stock | 1,500 | 2.13 | 3.2K | 13,000 | — | ↗ |
| 2022-06-07 | Wong Hing C | Officer | P-Purchase | A | Common Stock | 2,000 | 2.25 | 4.5K | 15,284,948 | — | ↗ |
| 2022-06-06 | Winer Gary M | Director | P-Purchase | A | Common Stock | 1,000 | 2.10 | 2.1K | 9,500 | — | ↗ |
| 2022-06-02 | Greene Rick S. | Director | P-Purchase | A | Common Stock | 4,800 | 2.09 | 10.0K | 8,411 | — | ↗ |
| 2022-05-31 | Jiao Jin-an | Officer | M-Exempt | A | Common Stock | 1,714 | 0.21 | 359.94 | 45,141 | — | ↗ |
| 2022-01-14 | Rhode Peter | Officer | M-Exempt | A | Common Stock | 1,714 | 0.21 | 359.94 | 48,499 | — | ↗ |
| 2021-12-06 | Jiao Jin-an | Officer | P-Purchase | A | Common Stock | 10,000 | 2.42 | 24.2K | 30,571 | — | ↗ |
| 2021-12-01 | Flowers Lee | Officer | M-Exempt | A | Common Stock | 4,285 | 0.14 | 599.90 | 95,952 | — | ↗ |
| 2021-11-23 | Byam Rebecca | Officer | M-Exempt | A | Common Stock | 27,000 | 0.14 | 3.8K | 89,000 | — | ↗ |
| 2021-10-26 | Winer Gary M | Director | A-Award | A | Stock Option | 37,037 | 2.70 | 100.0K | 37,037 | — | ↗ |
| 2021-10-26 | Giles Lisa M. | Director | A-Award | A | Stock Option | 37,037 | 2.70 | 100.0K | 37,037 | — | ↗ |
| 2021-09-15 | Medmira Capital Ltd. | 10% Owner | J-Other | D | Common Stock | 3,587,659 | 0.00 | — | 0 | — | ↗ |
| 2021-09-08 | Wong Hing C | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 800,000 | 4.31 | 3.45M | 800,000 | — | ↗ |
| 2021-09-08 | Rhode Peter | Officer | A-Award | A | Stock Option (Right to Buy) | 20,000 | 4.31 | 86.2K | 20,000 | — | ↗ |
| 2021-09-08 | Jiao Jin-an | Officer | A-Award | A | Stock Option (Right to Buy) | 10,000 | 4.31 | 43.1K | 10,000 | — | ↗ |
| 2021-09-08 | Flowers Lee | Officer | A-Award | A | Stock Option (Right to Buy) | 50,000 | 4.31 | 215.5K | 50,000 | — | ↗ |
| 2021-09-08 | Byam Rebecca | Officer | A-Award | A | Stock Option (Right to Buy) | 80,000 | 4.31 | 344.8K | 80,000 | — | ↗ |
| 2021-08-31 | Wong Hing C | Director / Officer | P-Purchase | A | Common Stock | 5,830 | 3.94 | 23.0K | 15,281,948 | — | ↗ |
| 2021-08-30 | Wong Hing C | Director / Officer | P-Purchase | A | Common Stock | 6,000 | 3.93 | 23.6K | 15,274,118 | — | ↗ |
| 2021-08-29 | Byam Rebecca | Officer | A-Award | A | Stock Option (Right to Buy) | 135,000 | 4.00 | 540.0K | 135,000 | — | ↗ |
| 2021-08-27 | Wong Hing C | Director / Officer | P-Purchase | A | Common Stock | 6,000 | 3.77 | 22.6K | 15,268,118 | — | ↗ |
| 2021-08-26 | Wong Hing C | Director / Officer | P-Purchase | A | Common Stock | 6,500 | 3.84 | 25.0K | 15,262,118 | — | ↗ |
| 2021-08-25 | Greene Rick S. | Director | P-Purchase | A | Common Stock | 3,611 | 4.10 | 14.8K | 3,611 | — | ↗ |
| 2021-08-23 | Flowers Lee | Officer | P-Purchase | A | Common Stock | 5,605 | 3.95 | 22.2K | 91,667 | — | ↗ |
| 2021-08-20 | Flowers Lee | Officer | P-Purchase | A | Common Stock | 7,853 | 4.08 | 32.1K | 86,062 | — | ↗ |
| 2021-08-19 | Flowers Lee | Officer | P-Purchase | A | Common Stock | 10,532 | 4.25 | 44.8K | 78,209 | — | ↗ |
| 2021-08-19 | Byam Rebecca | Officer | P-Purchase | A | Common Stock | 10,000 | 4.40 | 44.0K | 62,000 | — | ↗ |
| 2021-07-22 | Wong Hing C | Director / Officer | C-Conversion | D | Series A Redeemable Preferred Stock | 6,316,691 | 0.00 | — | 0 | — | ↗ |
| 2021-07-22 | Rhode Peter | Officer | P-Purchase | A | Common Stock | 12,500 | 8.00 | 100.0K | 46,785 | — | ↗ |
| 2021-07-22 | Medmira Capital Ltd. | 10% Owner | C-Conversion | D | Series C Redeemable Preferred Stock | 730,519 | 0.00 | — | 0 | — | ↗ |
| 2021-07-22 | Greene Rick S. | Director | A-Award | A | Stock Option | 20,964 | 4.77 | 100.0K | 20,964 | — | ↗ |
| 2021-07-22 | GARRETT SCOTT T | Director | P-Purchase | A | Common Stock | 125,000 | 8.00 | 1.00M | 125,000 | — | ↗ |
| 2021-07-22 | Flowers Lee | Officer | P-Purchase | A | Common Stock | 31,250 | 8.00 | 250.0K | 67,677 | — | ↗ |
| 2021-07-22 | Byam Rebecca | Officer | P-Purchase | A | Common Stock | 25,000 | 8.00 | 200.0K | 52,000 | — | ↗ |
| 2021-07-19 | Wong Hing C | Director / Officer | — | D | Common Stock | 0 | 0.00 | — | 4,285,714 | — | ↗ |
| 2021-07-19 | Rhode Peter | Officer | — | D | Stock Option (Right to Buy) | 8,571 | 0.21 | 1.8K | 0 | — | ↗ |
| 2021-07-19 | Medmira Capital Ltd. | 10% Owner | — | D | Series B Redeemable Preferred Stock | 2,857,142 | 0.00 | — | 0 | — | ↗ |
| 2021-07-19 | Jiao Jin-an | Officer | — | D | Stock Option (Right to Buy) | 30,857 | 0.14 | 4.3K | 0 | — | ↗ |
| 2021-07-19 | Greene Rick S. | Director | — | D | Common Stock | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-07-19 | GARRETT SCOTT T | Director | — | D | Common Stock | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-07-19 | Flowers Lee | Officer | — | D | Common Stock | 0 | 0.00 | — | 36,427 | — | ↗ |
| 2021-07-19 | Byam Rebecca | Officer | — | D | Common Stock | 0 | 0.00 | — | 27,000 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-1.9K
Shares Outstanding
2.09M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Hing C. Wong, Ph.D. Chief Executive Officer | 421.8K | — | — | — | — | 16.9K | 438.7K | 0.00% | ↗ |
| 2 | 2025 | Rebecca Byam Chief Financial Officer | 297.4K | — | — | — | — | 11.9K | 309.3K | 0.00% | ↗ |
| 3 | 2025 | Peter Rhode, Ph.D. Chief Scientific Officer and Vice President of Clinical Operations | 253.7K | — | — | — | — | 10.2K | 263.9K | 0.00% | ↗ |
| 4 | 2024 | Hing C. Wong, Ph.D. Chief Executive Officer | 349.2K | 5.0K | — | — | — | 14.0K | 368.2K | 0.00% | ↗ |
| 5 | 2024 | Peter Rhode, Ph.D. Chief Scientific Officer and Vice President of Clinical Operations | 246.8K | 5.0K | — | — | — | 9.9K | 261.7K | 0.00% | ↗ |
| 6 | 2024 | Rebecca Byam Chief Financial Officer | 143.5K | 5.0K | — | — | — | 5.7K | 154.2K | 0.00% | ↗ |
| 7 | 2023 | Hing C. Wong, Ph.D. Chief Executive Officer | 409.5K | — | — | — | — | 16.4K | 425.9K | 0.00% | ↗ |
| 8 | 2023 | Rebecca Byam Chief Financial Officer | 288.8K | — | — | — | — | 11.6K | 330.3K | 0.00% | ↗ |
| 9 | 2023 | Peter Rhode, Ph.D. Chief Scientific Officer and Vice President of Clinical Operations | 241.5K | — | — | — | — | 9.7K | 251.2K | 0.00% | ↗ |
| 10 | 2022 | Hing C. Wong, Ph.D. Chief Executive Officer | 404.3K | — | — | — | — | 16.8K | 421.1K | 0.00% | ↗ |
| 11 | 2022 | Rebecca Byam Chief Financial Officer | 285.0K | — | — | — | — | 12.0K | 297.1K | 0.00% | ↗ |
| 12 | 2022 | Peter Rhode, Ph.D. Chief Scientific Officer and Vice President of Clinical Operations | 238.4K | — | — | — | — | 10.2K | 248.6K | 0.00% | ↗ |
| 13 | 2021 | Hing C. Wong, Ph.D. Chief Executive Officer | 374.0K | — | — | 2.46M | 117.0K | 19.6K | 2.97M | 82.82% | ↗ |
| 14 | 2021 | Rebecca Byam Chief Financial Officer | 275.0K | — | — | 624.6K | 68.8K | 13.8K | 982.1K | 63.60% | ↗ |
| 15 | 2021 | Peter Rhode, Ph.D. Chief Scientific Officer and Vice President of Clinical Operations | 227.1K | — | — | 61.6K | — | 9.1K | 297.8K | 20.67% | ↗ |
| 16 | 2020 | Hing C. Wong, Ph.D. Chief Executive Officer | 360.0K | — | — | — | — | 14.4K | 374.4K | 0.00% | ↗ |
| 17 | 2020 | Rebecca Byam Chief Financial Officer | 275.0K | — | — | 18.9K | — | 11.0K | 304.9K | 6.20% | ↗ |
| 18 | 2020 | Peter Rhode, Ph.D. Chief Scientific Officer and Vice President of Clinical Operations | 219.7K | — | — | 13.8K | — | 8.8K | 242.3K | 5.70% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Hing C. Wong | Founder, Chief Executive Officer, Director & Secretary | 438.7K | — |
| Rebecca Byam | Chief Financial Officer | 308.9K | female |
| Peter Rhode | Chief Scientific Officer & Vice President of Clinical Operations | 263.9K | — |
| Lee D. Flowers | Senior Vice President of Business Development | — | male |
| Nicole Valdivieso | Vice President of Legal Affairs | — | female |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for HCWB
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
